The point-of-care-testing (poct) market size has grown rapidly in recent years. It will grow from $50.79 billion in 2025 to $56.68 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, increasing need for rapid clinical decision making, growth in emergency and critical care services, limited access to centralized laboratories, demand for immediate diagnostic results.
The point-of-care-testing (poct) market size is expected to see rapid growth in the next few years. It will grow to $86.91 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to advancement in poct device miniaturization, expansion of home care and remote patient monitoring, growing infectious disease outbreaks, increasing healthcare decentralization, rising adoption of self-testing diagnostics. Major trends in the forecast period include growing adoption of rapid diagnostic testing at point of care, rising demand for home-based and self-testing solutions, expansion of over-the-counter diagnostic products, increasing focus on early disease detection and screening, improved accuracy and sensitivity of poct devices.
The growing adoption of telemedicine is expected to drive the growth of the point-of-care testing (POCT) market in the coming years. Telemedicine involves delivering medical care remotely using digital communication technologies such as video calls, phone consultations, or secure messaging. Its adoption has accelerated due to rising demand for convenient, timely, and contact-free healthcare services, particularly following the COVID-19 pandemic. POCT supports telemedicine by providing rapid and reliable diagnostic results that can be shared instantly with remote healthcare providers, enabling timely clinical decisions. For example, in April 2025, the American Hospital Association, a U.S.-based professional organization, reported that in 2023, over 12.6% of Medicare beneficiaries utilized telehealth services. By 2036, the number of physicians is projected to reach 86,000, highlighting telehealth’s crucial role in addressing the growing physician shortage. Consequently, the increasing adoption of telemedicine is fueling the growth of the POCT market.
Major companies in the point-of-care testing (POCT) market are increasingly emphasizing technological innovations, such as microfluidic rapid antimicrobial-susceptibility testing (AST) systems, to meet the growing demand for faster, clinic-level diagnostics and enhanced antimicrobial stewardship in primary care. Microfluidic AST technology uses micrometer-scale fluid channels to culture and detect bacteria from patient samples - such as urine - and determine their antibiotic susceptibility far more quickly than conventional culture-based methods, which typically take several days. For instance, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, launched the PA 100 AST System, a compact POCT analyzer that uses Sysmex Astrego’s proprietary microfluidic cartridges to detect bacteria in roughly 15 minutes and deliver complete AST results in about 30 minutes. The system is highly user-friendly: healthcare professionals place the sample into a single-use cartridge, insert it into the desktop analyzer, and receive automated AST readouts without requiring specialized laboratory training. This rapid turnaround enables timely antibiotic decisions during the initial patient visit, supporting efforts to reduce inappropriate prescriptions and combat antimicrobial resistance (AMR).
In August 2024, Quest Diagnostics Inc., a US-based medical laboratory company, acquired LifeLabs LP for $1 billion (CAN $1.35 billion). This acquisition expands Quest Diagnostics’ POCT offerings and strengthens access to innovative diagnostic solutions. LifeLabs LP is a Canada-based provider of point-of-care testing services.
Major companies operating in the point-of-care-testing (poct) market are Johnson & Johnson, F. Hoffmann‑La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, BioMérieux SA, QuidelOrtho Corporation, Sysmex Corporation, Nova Biomedical Corporation, LifeScan Inc., Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Trinity Biotech Plc, Sinocare Inc., Menarini Diagnostics, Princeton BioMeditech, Helena Laboratories, Chembio Diagnostics, ARKRAY, Accriva, ACON Laboratories, Sekisui Diagnostics, PTS Diagnostics, Meridian Bioscience.
North America was the largest region in the point-of-care testing (POCT) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care-testing (poct) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care-testing (poct) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the point-of-care testing market by increasing costs of imported diagnostic devices, reagents, and electronic components used in POCT systems. Segments such as molecular diagnostics, PCR testing, and immunoassay-based devices are most affected, particularly in Asia-Pacific and North America where cross-border trade of medical diagnostics is high. These cost pressures have impacted pricing and slowed adoption in cost-sensitive markets. However, tariffs have also encouraged local manufacturing, regional supply chain development, and innovation in cost-effective POCT solutions.
The point-of-care-testing (poct) market research report is one of a series of new reports that provides point-of-care-testing (poct) market statistics, including point-of-care-testing (poct) industry global market size, regional shares, competitors with a point-of-care-testing (poct) market share, detailed point-of-care-testing (poct) market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care-testing (poct) industry. This point-of-care-testing (poct) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point-of-care testing (POCT) refers to diagnostic testing conducted at or near the site of patient care, providing immediate results and enabling faster clinical decision-making. Its purpose is to deliver quick and accurate diagnostic information directly at the point of care, facilitating timely treatment and improved patient outcomes.
The primary types of point-of-care testing (POCT) include blood glucose testing, infectious disease testing, cardiac marker testing, coagulation testing, pregnancy and fertility testing, blood gas or electrolyte testing, urinalysis testing, and others. Blood glucose testing involves measuring the amount of sugar (glucose) in a person’s blood to monitor and manage related conditions. POCT products are available through various purchase modes, including over-the-counter and prescription-based products, and utilize technologies such as immunoassays, molecular diagnostics, microbial detection, polymerase chain reaction (PCR) testing, and biochemical testing. Key end users include clinical laboratories, ambulatory care facilities, physician offices, pharmacies, retail clinics, e-commerce platforms, hospitals, critical care centers, urgent care centers, home care and self-testing, and others.
The point-of-care testing (POCT) market includes revenues earned by entities by providing services such as on-site diagnostic testing, rapid disease detection, mobile health screening, and patient self-testing support. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care testing (POCT) market includes sales of portable HbA1c analyzers, handheld blood gas analyzers, CRP (C-reactive protein) test kits, multiplex respiratory pathogen detection kits, and lateral flow urine analysis devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The point-of-care-testing (poct) market size is expected to see rapid growth in the next few years. It will grow to $86.91 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to advancement in poct device miniaturization, expansion of home care and remote patient monitoring, growing infectious disease outbreaks, increasing healthcare decentralization, rising adoption of self-testing diagnostics. Major trends in the forecast period include growing adoption of rapid diagnostic testing at point of care, rising demand for home-based and self-testing solutions, expansion of over-the-counter diagnostic products, increasing focus on early disease detection and screening, improved accuracy and sensitivity of poct devices.
The growing adoption of telemedicine is expected to drive the growth of the point-of-care testing (POCT) market in the coming years. Telemedicine involves delivering medical care remotely using digital communication technologies such as video calls, phone consultations, or secure messaging. Its adoption has accelerated due to rising demand for convenient, timely, and contact-free healthcare services, particularly following the COVID-19 pandemic. POCT supports telemedicine by providing rapid and reliable diagnostic results that can be shared instantly with remote healthcare providers, enabling timely clinical decisions. For example, in April 2025, the American Hospital Association, a U.S.-based professional organization, reported that in 2023, over 12.6% of Medicare beneficiaries utilized telehealth services. By 2036, the number of physicians is projected to reach 86,000, highlighting telehealth’s crucial role in addressing the growing physician shortage. Consequently, the increasing adoption of telemedicine is fueling the growth of the POCT market.
Major companies in the point-of-care testing (POCT) market are increasingly emphasizing technological innovations, such as microfluidic rapid antimicrobial-susceptibility testing (AST) systems, to meet the growing demand for faster, clinic-level diagnostics and enhanced antimicrobial stewardship in primary care. Microfluidic AST technology uses micrometer-scale fluid channels to culture and detect bacteria from patient samples - such as urine - and determine their antibiotic susceptibility far more quickly than conventional culture-based methods, which typically take several days. For instance, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, launched the PA 100 AST System, a compact POCT analyzer that uses Sysmex Astrego’s proprietary microfluidic cartridges to detect bacteria in roughly 15 minutes and deliver complete AST results in about 30 minutes. The system is highly user-friendly: healthcare professionals place the sample into a single-use cartridge, insert it into the desktop analyzer, and receive automated AST readouts without requiring specialized laboratory training. This rapid turnaround enables timely antibiotic decisions during the initial patient visit, supporting efforts to reduce inappropriate prescriptions and combat antimicrobial resistance (AMR).
In August 2024, Quest Diagnostics Inc., a US-based medical laboratory company, acquired LifeLabs LP for $1 billion (CAN $1.35 billion). This acquisition expands Quest Diagnostics’ POCT offerings and strengthens access to innovative diagnostic solutions. LifeLabs LP is a Canada-based provider of point-of-care testing services.
Major companies operating in the point-of-care-testing (poct) market are Johnson & Johnson, F. Hoffmann‑La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, BioMérieux SA, QuidelOrtho Corporation, Sysmex Corporation, Nova Biomedical Corporation, LifeScan Inc., Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Trinity Biotech Plc, Sinocare Inc., Menarini Diagnostics, Princeton BioMeditech, Helena Laboratories, Chembio Diagnostics, ARKRAY, Accriva, ACON Laboratories, Sekisui Diagnostics, PTS Diagnostics, Meridian Bioscience.
North America was the largest region in the point-of-care testing (POCT) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care-testing (poct) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care-testing (poct) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the point-of-care testing market by increasing costs of imported diagnostic devices, reagents, and electronic components used in POCT systems. Segments such as molecular diagnostics, PCR testing, and immunoassay-based devices are most affected, particularly in Asia-Pacific and North America where cross-border trade of medical diagnostics is high. These cost pressures have impacted pricing and slowed adoption in cost-sensitive markets. However, tariffs have also encouraged local manufacturing, regional supply chain development, and innovation in cost-effective POCT solutions.
The point-of-care-testing (poct) market research report is one of a series of new reports that provides point-of-care-testing (poct) market statistics, including point-of-care-testing (poct) industry global market size, regional shares, competitors with a point-of-care-testing (poct) market share, detailed point-of-care-testing (poct) market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care-testing (poct) industry. This point-of-care-testing (poct) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point-of-care testing (POCT) refers to diagnostic testing conducted at or near the site of patient care, providing immediate results and enabling faster clinical decision-making. Its purpose is to deliver quick and accurate diagnostic information directly at the point of care, facilitating timely treatment and improved patient outcomes.
The primary types of point-of-care testing (POCT) include blood glucose testing, infectious disease testing, cardiac marker testing, coagulation testing, pregnancy and fertility testing, blood gas or electrolyte testing, urinalysis testing, and others. Blood glucose testing involves measuring the amount of sugar (glucose) in a person’s blood to monitor and manage related conditions. POCT products are available through various purchase modes, including over-the-counter and prescription-based products, and utilize technologies such as immunoassays, molecular diagnostics, microbial detection, polymerase chain reaction (PCR) testing, and biochemical testing. Key end users include clinical laboratories, ambulatory care facilities, physician offices, pharmacies, retail clinics, e-commerce platforms, hospitals, critical care centers, urgent care centers, home care and self-testing, and others.
The point-of-care testing (POCT) market includes revenues earned by entities by providing services such as on-site diagnostic testing, rapid disease detection, mobile health screening, and patient self-testing support. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care testing (POCT) market includes sales of portable HbA1c analyzers, handheld blood gas analyzers, CRP (C-reactive protein) test kits, multiplex respiratory pathogen detection kits, and lateral flow urine analysis devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Point-of-Care-Testing (POCT) Market Characteristics
3. Point-of-Care-Testing (POCT) Market Supply Chain Analysis
4. Global Point-of-Care-Testing (POCT) Market Trends and Strategies
5. Point-of-Care-Testing (POCT) Market Analysis of End Use Industries
7. Global Point-of-Care-Testing (POCT) Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Point-of-Care-Testing (POCT) Total Addressable Market (TAM) Analysis for the Market
9. Point-of-Care-Testing (POCT) Market Segmentation
10. Point-of-Care-Testing (POCT) Market Regional and Country Analysis
11. Asia-Pacific Point-of-Care-Testing (POCT) Market
12. China Point-of-Care-Testing (POCT) Market
13. India Point-of-Care-Testing (POCT) Market
14. Japan Point-of-Care-Testing (POCT) Market
15. Australia Point-of-Care-Testing (POCT) Market
16. Indonesia Point-of-Care-Testing (POCT) Market
17. South Korea Point-of-Care-Testing (POCT) Market
18. Taiwan Point-of-Care-Testing (POCT) Market
19. South East Asia Point-of-Care-Testing (POCT) Market
20. Western Europe Point-of-Care-Testing (POCT) Market
21. UK Point-of-Care-Testing (POCT) Market
22. Germany Point-of-Care-Testing (POCT) Market
23. France Point-of-Care-Testing (POCT) Market
24. Italy Point-of-Care-Testing (POCT) Market
25. Spain Point-of-Care-Testing (POCT) Market
26. Eastern Europe Point-of-Care-Testing (POCT) Market
27. Russia Point-of-Care-Testing (POCT) Market
28. North America Point-of-Care-Testing (POCT) Market
29. USA Point-of-Care-Testing (POCT) Market
30. Canada Point-of-Care-Testing (POCT) Market
31. South America Point-of-Care-Testing (POCT) Market
32. Brazil Point-of-Care-Testing (POCT) Market
33. Middle East Point-of-Care-Testing (POCT) Market
34. Africa Point-of-Care-Testing (POCT) Market
36. Point-of-Care-Testing (POCT) Market Competitive Landscape and Company Profiles
37. Point-of-Care-Testing (POCT) Market Other Major and Innovative Companies
40. Point-of-Care-Testing (POCT) Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Point-Of-Care-Testing (POCT) Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses point-of-care-testing (poct) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for point-of-care-testing (poct)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point-of-care-testing (poct) market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Blood Glucose Testing; Infectious Diseases Testing; Cardiac Markers Testing; Coagulation Testing; Pregnancy And Fertility Testing; Blood Gas Or Electrolytes Testing; Urinalysis Testing; Other Types2) By Mode Of Purchase: Over-The-Counter Products; Prescribed Based Products
3) By Technology: Immunoassays; Molecular Diagnostics; Microbial Detection; Polymerase Chain Reaction (PCR) Testing; Biochemical Testing
4) By End-User: Clinical Laboratories; Ambulatory Care Facilities And Physician Offices; Pharmacies; Retail Clinics And E-Comm Platforms; Hospitals; Critical Care Centres; Urgent Care Centres; Home Care And Self-Testing; Other End-Users
Subsegments:
1) By Blood Glucose Testing: Self-Monitoring Blood Glucose Devices; Continuous Glucose Monitoring Devices; Flash Glucose Monitoring Devices2) By Infectious Diseases Testing: Human Immunodeficiency Virus (HIV) Testing; Hepatitis Testing; Influenza Testing; COVID-19 Testing; Other Infectious Diseases Testing
3) By Cardiac Markers Testing: Troponin Testing; Creatine Kinase-MB (CK-MB) Testing; Myoglobin Testing; B-type Natriuretic Peptide (BNP) Testing
4) By Coagulation Testing: Prothrombin Time (PT) Testing; Activated Partial Thromboplastin Time (aPTT) Testing; International Normalized Ratio (INR) Testing
5) By Pregnancy And Fertility Testing: Pregnancy Test Kits; Ovulation Test Kits; Fertility Hormone Testing
6) By Blood Gas Or Electrolytes Testing: Arterial Blood Gas Testing; Venous Blood Gas Testing; Electrolyte Testing
7) By Urinalysis Testing: Urine Chemistry Analysis; Microscopic Urine Analysis; Urine Culture Testing
8) By Other Types: Drug Abuse Testing; Allergy Testing; Cholesterol Testing; Thyroid Function Testing
Companies Mentioned: Johnson & Johnson; F. Hoffmann‑La Roche Ltd.; Abbott Laboratories; Danaher Corporation; Siemens Healthineers AG; Becton Dickinson and Company; BioMérieux SA; QuidelOrtho Corporation; Sysmex Corporation; Nova Biomedical Corporation; LifeScan Inc.; Ascensia Diabetes Care Holdings AG; Trividia Health Inc.; Trinity Biotech Plc; Sinocare Inc.; Menarini Diagnostics; Princeton BioMeditech; Helena Laboratories; Chembio Diagnostics; ARKRAY; Accriva; ACON Laboratories; Sekisui Diagnostics; PTS Diagnostics; Meridian Bioscience
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Point-of-Care-Testing (POCT) market report include:- Johnson & Johnson
- F. Hoffmann‑La Roche Ltd.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers AG
- Becton Dickinson and Company
- BioMérieux SA
- QuidelOrtho Corporation
- Sysmex Corporation
- Nova Biomedical Corporation
- LifeScan Inc.
- Ascensia Diabetes Care Holdings AG
- Trividia Health Inc.
- Trinity Biotech Plc
- Sinocare Inc.
- Menarini Diagnostics
- Princeton BioMeditech
- Helena Laboratories
- Chembio Diagnostics
- ARKRAY
- Accriva
- ACON Laboratories
- Sekisui Diagnostics
- PTS Diagnostics
- Meridian Bioscience
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 56.68 Billion |
| Forecasted Market Value ( USD | $ 86.91 Billion |
| Compound Annual Growth Rate | 11.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
